PAX2 and endometrium neoplasm: Although PAX2’s expansive impacts on the enhancer landscape and transcriptional reprogramming rationalize its activity as an endometrial tumor suppressor and argue against the overriding significance of individual genes, PGR stood out as a potentially significant target, whose expression significantly increased (6.98 times; P,q < 0.00001) after PAX2 reexpression in Ishikawa (Supplemental Figure 5B).